158 related articles for article (PubMed ID: 10822225)
1. Use of a long-acting gonadotrophin-releasing hormone analogue in a postmenopausal woman with hyperandrogenism due to a hilus cell tumour.
Picón MJ; Lara JI; Sarasa JL; Recasens JD; Clouet R; Gonzalo MA; Rovira A
Eur J Endocrinol; 2000 Jun; 142(6):619. PubMed ID: 10822225
[TBL] [Abstract][Full Text] [Related]
2. Long-term remission of ovarian hyperandrogenism after short-term treatment with a gonadotropin-releasing hormone agonist.
Efstathiadou Z; Tsatsoulis A
Fertil Steril; 2001 Jan; 75(1):59-62. PubMed ID: 11163817
[TBL] [Abstract][Full Text] [Related]
3. Postmenopausal virilization in a woman with gonadotropin dependent ovarian hyperthecosis.
Manieri C; Di Bisceglie C; Fornengo R; Grosso T; Zumpano E; Calvo F; Berardengo E; Volante M; Papotti M
J Endocrinol Invest; 1998 Feb; 21(2):128-32. PubMed ID: 9585388
[TBL] [Abstract][Full Text] [Related]
4. Androgen suppressive effect of GnRH agonist in ovarian hyperthecosis and virilizing tumours.
Pascale MM; Pugeat M; Roberts M; Rousset H; Déchaud H; Dutrieux-Berger N; Tourniaire J
Clin Endocrinol (Oxf); 1994 Nov; 41(5):571-6. PubMed ID: 7828344
[TBL] [Abstract][Full Text] [Related]
5. Leydig-cell-tumor of the ovary that responded to GnRH-analogue administration - case report and review of the literature.
Klotz RK; Müller-Holzner E; Fessler S; Reimer DU; Zervomanolakis I; Seeber B; Mattle V; Wildt L
Exp Clin Endocrinol Diabetes; 2010 May; 118(5):291-7. PubMed ID: 20198556
[TBL] [Abstract][Full Text] [Related]
6. Hyperandrogenism in a postmenopausal woman: diagnostic and therapeutic challenges.
Cheng V; Doshi KB; Falcone T; Faiman C
Endocr Pract; 2011; 17(2):e21-5. PubMed ID: 21247854
[TBL] [Abstract][Full Text] [Related]
7. GnRH analogue use in postmenopausal hyperandrogenism: long-term remission.
Gueorguiev M; Grossman AB
Endocrine; 2012 Apr; 41(2):342-3. PubMed ID: 22124941
[No Abstract] [Full Text] [Related]
8. [A case of postmenopausal hyperandrogenism caused by a lipid cell tumor].
Witek A; Skałba P; Chełmicki Z; Pajak J
Wiad Lek; 2002; 55(1-2):125-30. PubMed ID: 12043310
[TBL] [Abstract][Full Text] [Related]
9. Gonadotropin-releasing hormone agonist treatment in postmenopausal women with hyperandrogenism of ovarian origin.
Vollaard ES; van Beek AP; Verburg FA; Roos A; Land JA
J Clin Endocrinol Metab; 2011 May; 96(5):1197-201. PubMed ID: 21307133
[TBL] [Abstract][Full Text] [Related]
10. Utilisation of gonadotrophin-releasing hormone (GnRH) analogue to differentiate ovarian from adrenal hyperandrogenism in postmenopausal women.
Bahaeldein E; Brassill MJ
Endocrinol Diabetes Metab Case Rep; 2018; 2018():. PubMed ID: 30481153
[TBL] [Abstract][Full Text] [Related]
11. An ovarian Leydig cell tumor of ultrasound negative in a postmenopausal woman with hirsutism and hyperandrogenism: A case report.
Chen M; Zhou W; Zhang Z; Zou Y; Li C
Medicine (Baltimore); 2018 Mar; 97(10):e0093. PubMed ID: 29517680
[TBL] [Abstract][Full Text] [Related]
12. Effects of a long-acting gonadotropin-releasing hormone analog on the pituitary-ovarian-adrenal axis in women with severe hirsutism.
Castelo-Branco C; Martínez de Osaba MJ; Martínez S; Fortuny A
Metabolism; 1996 Jan; 45(1):24-7. PubMed ID: 8544772
[TBL] [Abstract][Full Text] [Related]
13. Sertoli-Leydig cell tumors: hormonal profile after dynamic test with GnRH analogue: triptorelin represents a useful tool to evaluate tumoral hyperandrogenism.
Turra J; Granzotto M; Gallea M; Faggian D; Conte L; Litta P; Vettor R; Mioni R
Gynecol Endocrinol; 2015 Jan; 31(1):18-21. PubMed ID: 25299229
[TBL] [Abstract][Full Text] [Related]
14. Modified dexamethasone and gonadotropin-releasing hormone agonist (Dx-GnRHa) test in the evaluation of androgen source(s) in hirsute women.
Bidzińska B; Tworowska U; Demissie M; Milewicz A
Przegl Lek; 2000; 57(7-8):393-6. PubMed ID: 11109312
[TBL] [Abstract][Full Text] [Related]
15. Postmenopausal hyperandrogenism.
Yoldemir T
Climacteric; 2022 Apr; 25(2):109-117. PubMed ID: 33988479
[TBL] [Abstract][Full Text] [Related]
16. Pure leydig cell tumour of the ovary in a post-menopausal patient with severe hyperandrogenism and erythrocytosis.
Yetkin DO; Demirsoy ET; Kadioglu P
Gynecol Endocrinol; 2011 Apr; 27(4):237-40. PubMed ID: 20518640
[TBL] [Abstract][Full Text] [Related]
17. Is ovarian and adrenal venous catheterization and sampling helpful in the investigation of hyperandrogenic women?
Kaltsas GA; Mukherjee JJ; Kola B; Isidori AM; Hanson JA; Dacie JE; Reznek R; Monson JP; Grossman AB
Clin Endocrinol (Oxf); 2003 Jul; 59(1):34-43. PubMed ID: 12807501
[TBL] [Abstract][Full Text] [Related]
18. Long-term administration of gonadotropin-releasing hormone agonist and dexamethasone: assessment of the adrenal role in ovarian dysfunction.
Cedars MI; Steingold KA; de Ziegler D; Lapolt PS; Chang RJ; Judd HL
Fertil Steril; 1992 Mar; 57(3):495-500. PubMed ID: 1531463
[TBL] [Abstract][Full Text] [Related]
19. Dynamics of plasma gonadotropin and sex steroid release in polycystic ovarian disease after pituitary-ovarian inhibition with an analog of gonadotropin-releasing hormone.
Calogero AE; Macchi M; Montanini V; Mongioi A; Maugeri G; Vicari E; Coniglione F; Sipione C; D'Agata R
J Clin Endocrinol Metab; 1987 May; 64(5):980-5. PubMed ID: 3104389
[TBL] [Abstract][Full Text] [Related]
20. Physiological estrogen replacement may enhance the effectiveness of the gonadotropin-releasing hormone agonist in the treatment of hirsutism.
Carmina E; Janni A; Lobo RA
J Clin Endocrinol Metab; 1994 Jan; 78(1):126-30. PubMed ID: 8288696
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
